The Priority Review acceptance and absence of an AdCom are strong positive signals. Monitor for any FDA review updates or potential manufacturing/CMC questions ahead of the November 27 PDUFA. The stock may re-rate upward as approval probability increases. Watch for any competitive developments or regulatory setbacks in Europe.
Price Chart
Executive Summary
BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of November 27, 2026. The FDA is not planning an advisory committee meeting, and the company is poised to launch upon approval. This is a major regulatory milestone for a first-in-class therapy addressing a significant unmet need in a rare, progressive muscular dystrophy.
Key Facts
- FDA accepted NDA for BBP-418 with Priority Review; PDUFA target action date November 27, 2026.
- FDA not currently planning an advisory committee meeting to discuss the application.
- BBP-418 met all primary and secondary endpoints in Phase 3 FORTIFY trial at 12-month interim analysis.
- If approved, BBP-418 would be the first and only approved therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD.
- Approximately 7,000 individuals in the U.S. and Europe live with LGMD2I/R9 and other addressable α-dystroglycanopathies.
- BBP-418 has Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from FDA; may qualify for a Priority Review Voucher upon approval.
- Company intends to initiate clinical studies in patients under 12 years old and in LGMD2M/R13 and LGMD2U/R20.
Financial Impact
First-in-class therapy for ~7,000 patients in U.S./Europe; potential for significant revenue if approved, with pricing typical for rare disease drugs (often $100K-$500K+/year). No financial terms disclosed.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) at PDUFA date, particularly on CMC or safety grounds.
- Commercial uptake depends on pricing, reimbursement, and physician adoption for a novel therapy in a small patient population.
- Clinical data from ongoing pediatric and additional indication studies could reveal safety or efficacy issues.
- Competition from other LGMD therapies in development could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301817 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access